keyword
MENU ▼
Read by QxMD icon Read
search

Gnrh agonist trigger

keyword
https://www.readbyqxmd.com/read/28513550/hcg-triggering-in-art-an-evolutionary-concept
#1
REVIEW
Anat Hershko Klement, Adrian Shulman
Human chorionic gonadotropin (hCG) is no longer a single, omnipotent ovulation triggering option. Gonadotropin releasing hormone (GnRH) agonist, initially presented as a substitute for hCG, has led to a new era of administering GnRH agonist followed by hCG triggering. According to this new concept, GnRH agonist enables successful ovum maturation, while hCG supports the luteal phase and pregnancy until placental shift.
May 17, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28467768/gnrh-agonist-triggering-of-ovulation-replacing-hcg-a-30-year-old-revolution-in-ivf-practice-led-by-rambam-health-care-campus
#2
REVIEW
Shahar Kol, Ofer Fainaru
Final oocyte maturation is a crucial step in in vitro fertilization, traditionally achieved with a single bolus of human chorionic gonadotropin (hCG) given 36 hours before oocyte retrieval. This bolus exposes the patient to the risks of ovarian hyperstimulation syndrome (OHSS), particularly in the face of ovarian hyper-response to gonadotropins. Although multiple measures were developed to prevent OHSS, gonadotropin-releasing hormone (GnRH) agonist triggering is now globally recognized as the best approach to achieve this goal...
April 28, 2017: Rambam Maimonides Medical Journal
https://www.readbyqxmd.com/read/28459828/individual-luteolysis-pattern-after-gnrh-agonist-trigger-for-final-oocyte-maturation
#3
Barbara Lawrenz, Nicolas Garrido, Suzan Samir, Francisco Ruiz, Laura Melado, Human M Fatemi
Final oocyte maturation using GnRH-agonist trigger in a GnRH-antagonist protocol is increasingly common, as ovarian hyperstimulation syndrome is almost completely avoided. However, this approach might lead to reduced pregnancy rates due to severe luteolysis. This proof of concept study evaluated the extend of luteolysis by measuring progesterone levels 48 hours after oocyte retrieval in 51 patients, who received GnRH-agonist trigger for final oocyte maturation in a GnRH-antagonist protocol due to the risk of ovarian hyperstimulation syndrome...
2017: PloS One
https://www.readbyqxmd.com/read/28444614/combined-gnrh-agonist-and-human-chorionic-gonadotropin-trigger-improves-icsi-cycle-outcomes-in-patients-with-history-of-poor-fertilization
#4
Rony T Elias, Nigel Pereira, Lisa Artusa, Amelia G Kelly, Monica Pasternak, Jovana P Lekovich, Gianpiero D Palermo, Zev Rosenwaks
PURPOSE: The purpose of this study was to investigate the utility of a combined GnRH-agonist (GnRH-a) and human chorionic gonadotropin (hCG) trigger in improving ICSI cycle outcomes in patients with poor fertilization history after standard hCG trigger in prior ICSI cycles. METHODS: Retrospective cohort study. Patients with a fertilization rate of <20% in at least two prior ICSI cycles who subsequently underwent another ICSI cycle with hCG trigger were compared to those who underwent another ICSI cycle with a combined GnRH-a and hCG trigger...
April 13, 2017: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/28440715/gnrh-agonist-triggering-for-final-oocyte-maturation-in-gnrh-antagonist-ivf-cycles-induces-decreased-lh-pulse-rate-and-amplitude-in-early-luteal-phase-a-possible-luteolysis-mechanism
#5
Samer Tannus, Yechiel Burke, Christopher R McCartney, Shahar Kol
The use of GnRH agonist to trigger final oocyte maturation in GnRH-antagonist in vitro fertilization (IVF) cycles has been shown to significantly reduce or even eliminate the risk of ovarian hyperstimulation syndrome (OHSS) by inducing rapid luteolysis early in the luteal phase. The exact mechanism of this early luteolysis is still widely unknown. Since luteinizing hormone (LH) has a major role in corpus luteum support, we sought to explore the pattern of LH secretion early in the luteal phase. Ten high risk patients for developing OHSS and triggered with GnRH agonist were included...
April 25, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28440686/severe-ovarian-hyperstimulation-syndrome-after-combined-gnrh-agonist-and-low-dose-human-chorionic-gonadotropin-trigger-in-a-patient-with-a-single-kidney
#6
Nigel Pereira, Jovana P Lekovich, Isaac Kligman, Zev Rosenwaks
Ovarian hyperstimulation syndrome (OHSS) following gonadotropin-releasing hormone agonist (GnRH-a) trigger is rare. Here, we report a case of severe OHSS after combined GnRH-a and low-dose human chorionic gonadotropin (hCG) trigger in a patient with a single kidney. The patient is a 32-year-old women with a two-year history of infertility. The patient's history was significant for a single kidney, that is, she had donated a kidney to a family member three years ago. The patient underwent controlled ovarian stimulation (COS) for in vitro fertilization (IVF) and received a combined 2 mg GnRH-a and 1500 IU hCG ovulatory trigger...
April 25, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28427285/premenstrual-dysphoric-disorder-symptoms-following-ovarian-suppression-triggered-by-change-in-ovarian-steroid-levels-but-not-continuous-stable-levels
#7
Peter J Schmidt, Pedro E Martinez, Lynnette K Nieman, Deloris E Koziol, Karla D Thompson, Linda Schenkel, Paul G Wakim, David R Rubinow
OBJECTIVE: Premenstrual dysphoric disorder (PMDD) symptoms are eliminated by ovarian suppression and stimulated by administration of ovarian steroids, yet they appear with ovarian steroid levels indistinguishable from those in women without PMDD. Thus, symptoms could be precipitated either by an acute change in ovarian steroid levels or by stable levels above a critical threshold playing a permissive role in expression of an underlying infradian affective "pacemaker." The authors attempted to determine which condition triggers PMDD symptoms...
April 21, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28416291/cumulative-live-birth-rate-after-gnrh-agonist-trigger-and-elective-cryopreservation-of-all-embryos-in-high-responders
#8
Veljko Vlaisavljević, Borut Kovačič, Jure Knez
Elective embryo cryopreservation after using gonadotrophin-releasing hormone (GnRH) antagonist protocols and GnRH agonist triggering is becoming an increasingly important part of medically assisted reproduction. We designed a single-centre retrospective study to assess the cumulative probability of achieving a live birth through consecutive transfers of vitrified-warmed blastocysts after elective embryo cryopreservation in high-responding patients. Hence, 123 women identified to be at high risk for developing ovarian hyperstimulation syndrome were included...
April 7, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28393578/kisspeptin-as-a-promising-oocyte-maturation-trigger-for-in-vitro-fertilisation-in-humans
#9
Miro Kasum, Daniela Franulić, Ermin Čehić, Slavko Orešković, Albert Lila, Emina Ejubović
The aim of this review is to analyse the effectiveness of exogenous kisspeptin administration as a novel alternative of triggering oocyte maturation, instead of currently used triggers such as human chorionic gonadotropin (hCG) or gonadotropin releasing hormone (GnRH) agonist, in women undergoing in vitro fertilisation (IVF) treatment. Kisspeptin has been considered a master regulator of two modes of GnRH and hence gonadotropin secretion, pulses and surges. Administration of kisspeptin-10 and kisspeptin-54 induces the luteinising hormone (LH) surge required for egg maturation and ovulation in animal investigations and LH release during the preovulatory phase of the menstrual cycle and hypothalamic amenorrhoea in humans...
April 10, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28360822/impact-of-blood-hypercoagulability-on-in-vitro-fertilization-outcomes-a-prospective-longitudinal-observational-study
#10
Grigoris T Gerotziafas, Patrick Van Dreden, Emmanuelle Mathieu d'Argent, Eleftheria Lefkou, Matthieu Grusse, Marjorie Comtet, Rabiatou Sangare, Hela Ketatni, Annette K Larsen, Ismail Elalamy
BACKGROUND: Blood coagulation plays a crucial role in the blastocyst implantation process and its alteration may be related to in vitro fertilization (IVF) failure. We conducted a prospective observational longitudinal study in women eligible for IVF to explore the association between alterations of coagulation with the IVF outcome and to identify the biomarkers of hypercoagulability which are related with this outcome. METHODS: Thirty-eight women eligible for IVF (IVF-group) and 30 healthy, age-matched women (control group) were included...
2017: Thrombosis Journal
https://www.readbyqxmd.com/read/28351814/combining-several-interventions-to-reduce-the-incidence-of-ohss-a-prospective-cohort-study
#11
Mohamed Elmahdy, Eman A Abdelsalam, Hassan A Maghraby
OBJECTIVE: To assess the outcome of using low-dose aspirin, dopamine agonist and triggering ovulation by low dose of HCG in combination with GnRH agonist in fixed GnRH antagonist protocol in patients at risk of OHSS. STUDY DESIGN: This prospective cohort study was conducted on 50 infertile women who were at high risk of OHSS. They received low dose aspirin from first day of stimulation, cabergoline 0.5mg daily from the day of HCG for 8days and low dose of HCG (2500 IU) in combination with GnRH agonist for final oocyte maturation in fixed GnRH antagonist protocol...
May 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28333356/the-safety-and-efficacy-of-controlled-ovarian-hyperstimulation-for-fertility-preservation-in-women-with-early-breast-cancer-a-systematic-review
#12
Rachael J Rodgers, Geoffrey D Reid, Juliette Koch, Rebecca Deans, William L Ledger, Michael Friedlander, Robert B Gilchrist, Kirsty A Walters, Jason A Abbott
STUDY QUESTION: Can controlled ovarian hyperstimulation (COH) for fertility preservation be effectively conducted in women with breast cancer without worsening their prognosis? SUMMARY ANSWER: COH with co-administration of letrozole suppresses oestradiol levels without significantly impacting oocyte yield or decreasing disease-free survival rates. WHAT IS KNOWN ALREADY: Oestradiol has the capacity to stimulate the proliferation of breast cancer cells...
May 1, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28276192/the-pregnancy-outcome-of-progestin-primed-ovarian-stimulation-using-4-versus-10%C3%A2-mg-of-medroxyprogesterone-acetate-per-day-in-infertile-women-undergoing-in%C3%A2-vitro-fertilisation-a-randomised-controlled-trial
#13
J Dong, Y Wang, W R Chai, Q Q Hong, N L Wang, L H Sun, H Long, L Wang, H Tian, Q F Lyu, X F Lu, Q J Chen, Y P Kuang
OBJECTIVE: To investigate the clinical outcome and endocrinological characteristics of progestin-primed ovarian stimulation (PPOS) using 4 versus 10 mg of medroxyprogesterone acetate (MPA) per day in infertile women with normal ovary reserve. DESIGN: A randomised parallel controlled trial. SETTING: Tertiary-care academic medical centre. PARTICIPANTS: A cohort of 300 infertile women undergoing in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) treatment...
June 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28215488/gonadotropin-releasing-hormone-agonist-gnrha-trigger-state-of-the-art
#14
REVIEW
C Dosouto, T Haahr, P Humaidan
GnRH agonist (GnRHa) trigger for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI cycles significantly reduces the risk of ovarian hyperstimulation syndrome (OHSS). GnRHa trigger followed by modifications of the standard luteal phase support (modified luteal phase support) secures fresh transfer in the majority of patients with excellent reproductive outcomes. In freeze all cycles (segmented cycles) GnRHa trigger allows oocyte retrieval with a minimal risk of early onset OHSS and good reproductive outcomes in subsequent frozen thaw cycles...
February 16, 2017: Reproductive Biology
https://www.readbyqxmd.com/read/28130435/cumulative-live-birth-rates-after-one-art-cycle-including-all-subsequent-frozen-thaw-cycles-in-1050-women-secondary-outcome-of-an-rct-comparing-gnrh-antagonist-and-gnrh-agonist-protocols
#15
M Toftager, J Bogstad, K Løssl, L Prætorius, A Zedeler, T Bryndorf, L Nilas, A Pinborg
STUDY QUESTION: Are cumulative live birth rates (CLBRs) similar in GnRH-antagonist and GnRH-agonist protocols for the first ART cycle including all subsequent frozen-thaw cycles from the same oocyte retrieval? SUMMARY ANSWER: The chances of at least one live birth following utilization of all fresh and frozen embryos after the first ART cycle are similar in GnRH-antagonist and GnRH-agonist protocols. WHAT IS KNOWN ALREADY: Reproductive outcomes of ART treatment are traditionally reported as pregnancies per cycle or per embryo transfer...
March 1, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28111738/interventions-for-the-prevention-of-ohss-in-art-cycles-an-overview-of-cochrane-reviews
#16
REVIEW
Selma Mourad, Julie Brown, Cindy Farquhar
BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) in assisted reproductive technology (ART) cycles is a treatment-induced disease that has an estimated prevalence of 20% to 33% in its mild form and 3% to 8% in its moderate or severe form. These numbers might even be higher for high-risk women such as those with polycystic ovaries or a high oocyte yield from ovum pickup. OBJECTIVES: The objective of this overview is to identify and summarise all evidence from Cochrane systematic reviews on interventions for prevention or treatment of moderate, severe and overall OHSS in couples with subfertility who are undergoing ART cycles...
January 23, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28056703/does-gnrh-agonist-triggering-control-painful-symptom-scores-during-assisted-reproductive-technology-a-retrospective-study
#17
Mathilde Bourdon, Pietro Santulli, Dominique de Ziegler, Vanessa Gayet, Chloé Maignien, Louis Marcellin, Charles Chapron
OBJECTIVE: The aim of this study was to assess the progression of pain symptoms during assisted reproductive technology (ART) cycles following administration of GnRH agonist (GnRHa) versus human chorionic gonadotrophin (hCG) triggering. DESIGN: Observational cohort study. SETTING: A tertiary care university hospital in France. POPULATION: Patients who underwent ART programs. METHODS: Between January 01, 2014, and June 31, 2014, 122 cycles were allocated to 2 groups: GnRHa triggering with a scheduled differed embryo transfer (n = 57) or hCG triggering with a fresh embryo transfer (n = 70)...
January 1, 2017: Reproductive Sciences
https://www.readbyqxmd.com/read/28050961/final-oocyte-maturation-in-assisted-reproduction-with-human-chorionic-gonadotropin-and-gonadotropin-releasing-hormone-agonist-dual-trigger
#18
REVIEW
Sofia Andrade de Oliveira, Vinícius Fernando Calsavara, Gemma Castillón Cortés
Final oocyte maturation with Human Chorionic Gonadotropin (hCG) and ovarian stimulation with Follicle Stimulation Hormone (FSH) combined with Gonadotrophin-releasing Hormone (GnRH) antagonist to block Luteinizing hormone (LH) surge is a standard procedure of in vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI). However, GnRH agonist has been replacing the use of hCG in certain situations, especially in patients at risk of Ovarian Hyperstimulation Syndrome (OHSS). Some studies have also shown advantages in the combined use of GnRH agonist concurrently with hCG in inducing final oocyte maturation, a treatment known as "Dual Trigger"...
December 1, 2016: JBRA Assisted Reproduction
https://www.readbyqxmd.com/read/28029396/standards-of-care-in-infertility-in-europe
#19
REVIEW
Christina I Messini, Alexandros Daponte, George Anifandis, Tahir Mahmood, Ioannis E Messinis
Evidence-based medicine is the principal approach to medical practice. There are several debatable issues in infertility, which require clarification. Over the past 20 years, reliable methodology has been developed for the management of infertile couples. This includes high quality diagnostic and therapeutic procedures, which are applied in highly specialised infertility centres. The European Board and College of Obstetrics and Gynaecology (EBCOG) has published Standards of Care for Women's Health in Europe, which should be the cornerstone for the clinicians and service providers in the European Union to establish common protocols within their centres...
October 20, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28019139/individual-luteolysis-post-gnrh-agonist-trigger-in-gnrh-antagonist-protocols
#20
B Lawrenz, F Ruiz, N Engelmann, H M Fatemi
Over the past few years, the use of Gonadotropin-releasing-hormone (GnRH)-agonist for final oocyte maturation in GnRH-antagonist-protocols in stimulated IVF/ICSI cycles has gained worldwide acceptance, as this approach reduces significantly the risk for development of ovarian hyperstimulation syndrome (OHSS). Final oocyte maturation with GnRH-agonist leads to sever luteolysis, which cannot be counterbalanced using standard luteal phase support with purely progesterone (P4) application and therefore administration of hCG or high doses of P4 is considered to be essential to prevent/counteract luteolysis...
April 2017: Gynecological Endocrinology
keyword
keyword
86339
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"